SRx Health Solutions, Inc. (NYSE American: SRXH) issues frequent press releases and SEC-referenced announcements that document its transition toward a digital-asset treasury operating model and its planned acquisition of EMJ Crypto Technologies Inc. (EMJX). The news flow provides insight into how the company is reshaping its strategy around a Gen2 digital-asset treasury platform that uses quantitative models, artificial intelligence and systematic risk controls.
Recent news items describe the definitive agreement to acquire EMJX, stockholder approval for a future name change to EMJX, Inc. and a planned ticker change to EMJX upon closing of the transaction. Company announcements also cover the deployment of an initial allocation of capital into digital assets such as Bitcoin and Ethereum, which the company characterizes as part of a measured, model-driven treasury management approach rather than short-term speculation.
Other SRXH news highlights enhancements to the EMJX platform, including integration of OpenAI large language models for research and risk decision support and the use of prediction-market probability data to strengthen its internal risk-intelligence framework. Governance and capital-markets updates appear regularly, such as the appointment of new directors with experience in cannabis, capital markets and cryptocurrency treasury strategies, amendments to the company’s charter to increase authorized shares, and private placements of preferred stock and warrants.
SRXH news releases also address NYSE American listing matters, including notifications of stockholders’ equity deficiencies and acceptance of the company’s plan to regain compliance with continued listing standards. For investors tracking SRXH, the news feed offers a consolidated view of transaction milestones, treasury activities, platform development and regulatory communications. Monitoring this page helps readers follow how the company’s proposed combination with EMJX progresses and how its digital-asset treasury strategy evolves over time.
SRX Global (SRXH) announced an initial investment of $2.5 million to seed a newly formed multi-strategy trading platform fund.
The platform was established as a joint venture between SRX's internal EMJX division and 5T Trading. It is to launch with managers from Millennium Management, Balyasny and Citadel under Eric Jackson's leadership. Jackson is President of the EMJX Platform and Head of Asset Management.
The company aims to support the next generation of proprietary traders, who trade with firm capital, through capital backing and trading infrastructure. The planned approach groups experienced managers into teams, described as pods, to provide guidance to future traders. SRX expects the venture to generate value for its portfolio; that is an expectation rather than a reported investment result.
SRX Global (NYSE American: SRXH) entered a definitive purchase agreement to acquire CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings. The pending transaction would make CERo Therapeutics wholly owned by SRX. SRX expects subsidiary-level fundraising through its CERO 1236 special-purpose vehicle without diluting existing SRX shareholders, and expects the acquisition to accelerate development of CER-1236 for blood cancers.
CERo has treated six patients in the Phase 1 CERTAIN-T trial. No dose-limiting toxicities were observed during the assessment period in the latest three-patient cohort at an increased dose. Results remain preliminary and do not establish safety or efficacy. The third planned cohort has begun, with patients being screened; it is expected to evaluate one billion cells per patient and include myelodysplastic syndromes and myelofibrosis.
SRX Global (SRXH) committed $1.5 million to launch a family of actively managed exchange-traded funds through its EMJX platform.
EMJX expects the first ETF, targeting retail and institutional investors, to become available in the first quarter of 2027. It will use a digital asset hedging strategy powered by EMJX’s proprietary AI model, designed to adjust exposure as market conditions change. Eric Jackson will manage the ETF family, while Kupa AI, co-founded by Andy Kim, will oversee launch logistics.
SRX intends to distribute its ETF holdings to shareholders as a dividend. Timing and the record date will be announced later.
SRX Global (SRXH) added an investment in Onconetix (ONCO) and updated shareholders on the liquidation of two portfolio holdings.
The holdings are Vistagen Therapeutics (VTGN) and Greenland Mines (GRML). SRX said it added Onconetix in anticipation of the closing of Onconetix's previously announced agreement to acquire Realbotix. Realbotix developed Vinci, an AI vision system that places cameras and tracking lenses inside robotic eyes. The system is described as detecting motion, recognizing returning users and identifying objects or colors.
SRX Global (SRXH) will present at the Webull Corporate Connect Series Fintech Investment Webinar on September 30, 2026.
The live session begins at 1:00 p.m. ET on the Webull platform. Speakers are CEO Kent Cunningham and Eric Jackson, president of the EMJX Platform and head of asset management. A replay will be available on Webull.
SRX Global (SRXH) provided a detailed update on portfolio company ARMR Sciences, whose lead vaccine candidate ARMR-100 is in a Phase 1/2 trial for fentanyl exposure. As of early September 2026, four patient cohorts have completed dosing, with no vaccine-related serious adverse events reported and a clear anti-fentanyl immune response observed, including a booster effect after the second dose. Dose escalation through Cohorts 3 and 4 is complete, and the first fentanyl challenge cohort is underway, aiming to identify doses for anticipated follow-on trials.
ARMR received a contract from the Department of War to co-develop a generative AI platform that uses historical preclinical and clinical data to accelerate medical countermeasure development and support potential FDA Animal Rule pathways. ARMR was also selected for the FDA’s Model-Informed Drug Development Paired Meeting Program, allowing in-depth discussion of predictive modeling in its regulatory strategy. SRX’s CEO characterizes these developments as strengthening the investment thesis and reducing risk across scientific and regulatory fronts.
SRX Global (NYSE American: SRXH) announced it has purchased senior secured debt in CERo Therapeutics Holdings (OTCQB: CERO), an immunotherapy company developing engineered T cell therapeutics. The investment is expected to give CERo additional capital and operational support to advance its clinical programs, including lead candidate CER-1236 for hematologic cancers.
According to CERo, six patients have been treated in the ongoing Phase 1 CERTAIN-T trial. In the most recent three-patient cohort at an increased dose, no dose-limiting toxicities were observed during the assessment period, and expansion of infused CER-1236 cells has been reported. CERo has started the third cohort, planned to evaluate one billion cells per patient and include patients with myelodysplastic syndromes and myelofibrosis. The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study assesses safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity in several hematologic malignancies, with safety as the primary endpoint.
SRX Global (NYSE American: SRXH) reported fiscal Q3 2026 net sales of $3.4 million, up 27% year over year, with operating loss improving 63% to $3.2 million and net loss from continuing operations narrowing to $4.1 million. Adjusted EBITDA loss improved 35% to $1.6 million.
As of June 30, 2026, SRX Global reported net asset value (NAV) of $62.9 million, or $3.22 per common share, exceeding preliminary estimates of $60.0 million and $3.07 per share. The company held $36.7 million in cash, cash equivalents and restricted cash, $65.2 million in current assets and $2.4 million in total liabilities, with no debt outstanding.
SRX Global completed the acquisition of EMJX, an AI-enabled digital-asset treasury platform, and strengthened Halo operations, achieving 98% June fill rates and record Prime Day results. The board approved a 10 million share repurchase program and a one-time $0.05 per-share cash dividend (~$1.3 million).
SRX Global (NYSE American: SRXH) will host a fiscal third quarter 2026 conference call on Thursday, August 13, 2026 at 4:30 p.m. ET to discuss results for the quarter ended June 30, 2026. The call will be accessible via webcast at the company’s investor relations calendar.
A recording link will be available after the event on SRX Global’s investor relations website. A Q&A session will follow the prepared remarks, focusing on pre-submitted questions sent to KCSA Strategic Communications at SRX@KCSA.com.
SRX Global (NYSE American: SRXH) announced it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), described as a late clinical-stage biopharmaceutical company developing nose-to-brain intranasal product candidates, called pherines, to address neurocircuitry involved in neuroscience indications.
According to SRX Global, it views Vistagen shares as undervalued and is open to constructive engagement with Vistagen’s leadership team and Board of Directors to discuss ideas for unlocking shareholder value. SRX Global describes itself as an AI-driven investment platform that uses proprietary technology, data analytics, and disciplined capital allocation to invest in high-conviction operating companies, strategic assets, and technology-enabled opportunities across multiple sectors.